IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
AHP
Indication
Adjuvant therapy following surgical resection of Kit (CD117) positive gastrointestinal stromal tumor
Kit (CD117)-positive gastrointestinal stromal tumors are mesenchymal neoplasms arising from the interstitial cells of Cajal within the digestive tract, most commonly in the stomach or small intestine. Read more about Adjuvant therapy following surgical resection of Kit (CD117) positive gastrointestinal stromal tumor
28 drugs 27 manufacturers
Drugs that treat it
Common Adjuvant therapy following surgical resection of Kit (CD117) positive gastrointestinal stromal tumor therapies.
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
AUROBINDO PHARM
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
ARMAS PHARMACEU
IMKELDI (imatinib mesylate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
SHORLA PHARMA I
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
QUALLENT PHARMA
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
BLUEPOINT/ONCOP
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
CAMBER PHARMACE
GLEEVEC (imatinib mesylate)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
Novartis Pharmaceuticals
IMATINIB MESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
SAFECOR HEALTH
Filter & compare in the drug finder →Opens the drug finder with Adjuvant therapy following surgical resection of Kit (CD117) positive gastrointestinal stromal tumor preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAbout Adjuvant therapy following surgical resection of Kit (CD117) positive gastrointestinal stromal tumor.
Kit (CD117)-positive gastrointestinal stromal tumors are mesenchymal neoplasms arising from the interstitial cells of Cajal within the digestive tract, most commonly in the stomach or small intestine.
Pathophysiologically, these tumors are characterized by cell-surface expression of the CD117 antigen, typically driven by activating mutations in the *KIT* proto-oncogene receptor tyrosine kinase that promote uncontrolled cellular proliferation.
In this post-surgical clinical state, patients who have undergone complete gross surgical resection of the primary tumor face a variable risk of disease recurrence depending on tumor size, mitotic rate, location, or tumor rupture.
Adjuvant therapy is indicated in this setting to eradicate residual micrometastatic disease and reduce the risk of relapse.
- ajmc.com
Kit (CD117)-positive gastrointestinal stromal tumors are mesenchymal neoplasms arising from the interstitial cells of Cajal within the digestive tract, most commonly in the stomach or small intestine Pathophysiologically, these tumors are characterized by cell-surface expression of the CD117 antigen, typically driven by activating mutations in the *KIT* proto-oncogene receptor tyrosine kinase that promote uncontrolled cellular proliferation
- nih.gov
Kit (CD117)-positive gastrointestinal stromal tumors are mesenchymal neoplasms arising from the interstitial cells of Cajal within the digestive tract, most commonly in the stomach or small intestine
- prnewswire.com
Pathophysiologically, these tumors are characterized by cell-surface expression of the CD117 antigen, typically driven by activating mutations in the *KIT* proto-oncogene receptor tyrosine kinase that promote uncontrolled cellular proliferation
- nih.gov
Pathophysiologically, these tumors are characterized by cell-surface expression of the CD117 antigen, typically driven by activating mutations in the *KIT* proto-oncogene receptor tyrosine kinase that promote uncontrolled cellular proliferation In this post-surgical clinical state, patients who have undergone complete gross surgical resection of the primary tumor face a variable risk of disease recurrence depending on tumor size, mitotic rate, location, or tumor rupture Adjuvant therapy is indic...
- fda.gov
In this post-surgical clinical state, patients who have undergone complete gross surgical resection of the primary tumor face a variable risk of disease recurrence depending on tumor size, mitotic rate, location, or tumor rupture
- ascopost.com
In this post-surgical clinical state, patients who have undergone complete gross surgical resection of the primary tumor face a variable risk of disease recurrence depending on tumor size, mitotic rate, location, or tumor rupture
- liferaftgroup.org
Adjuvant therapy is indicated in this setting to eradicate residual micrometastatic disease and reduce the risk of relapse
Personalize your experience
Follow Adjuvant therapy following surgical resection of Kit (CD117) positive gastrointestinal stromal tumor and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.